Gustavo E. Velásquez

Gustavo E. Velásquez

Auto-generated profile, based on publicly available information

Gustavo E. Velásquez

UCSF Center for Tuberculosis

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2018 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
GVGustavo E. Velásquez
Gustavo E. Velásquez
MBMeredith B. Brooks
Meredith B. Brooks
JCJulia M. Coit
Julia M. Coit
HPHenry Pertinez
Henry Pertinez
DVDante Vargas Vásquez
Dante Vargas Vásquez
CMCarole D. Mitnick
Carole D. Mitnick
Rationale: We examined whether increased rifampin doses could shorten standard therapy for tuberculosis without increased toxicity. Objectives: To assess the differences across three daily oral doses of rifampin in change in elimination rate of Mycobacterium tuberculosis in sputum and frequency of rifampin-related adverse events. Methods: We conducted a blinded, randomized, controlled Phase II clinical trial of 180 adults with new smear-positive pulmonary tuberculosis, susceptible to isoniazid and rifampin. We randomized 1:1:1 to 10, 15, and 20 mg/kg/day of rifampin during the intensive phase. We report the primary efficacy and safety endpoints: change in elimination rate of M. tuberculosis log10 colony forming units and frequency of grade 2 or higher rifampin-related adverse events. We report efficacy by treatment arm and by primary (AUC/MIC) and secondary (AUC) pharmacokinetic exposure. Measurements and Main Results: Each 5 mg/kg/day increase in rifampin dose resulted in differences of -0.011 (95%CI, -0.025 – +0.002;P=0.230) and -0.022 (95%CI, -0.046 – -0.002;P=0.022) log10 colony forming units/mL/day in the modified intention-to-treat and per-protocol analyses, respectively. Elimination rate in the per-protocol population increased significantly with rifampin AUC0-6 (P=0.011) but not with AUC0-6/MIC99.9 (P=0.053). Grade 2 or higher rifampin-related adverse events occurred with similar frequency across the three treatment arms: 26(43.3%), 31(51.7%), and 23(38.3%) participants had at least one event (P=0.7092) up to 4 weeks after the intensive phase. Treatment failed or disease recurred in 11(6.1%) participants. Conclusions: Our findings of more rapid sputum sterilization and similar toxicity with higher rifampin doses support investigation of increased rifampin doses to shorten tuberculosis treatment. Clinical trial registration available at www.clinicaltrials.gov, ID NCT01408914.

30 January 2025 in New England Journal of Medicine
Verified
Journal Article
Open access
LGLorenzo Guglielmetti
Lorenzo Guglielmetti
UKUzma Khan
Uzma Khan
GVGustavo E. Velásquez
Gustavo E. Velásquez
MGMaelenn Gouillou
Maelenn Gouillou
AAAmanzhan Abubakirov
Amanzhan Abubakirov
CMCarole D Mitnick
Carole D Mitnick
For decades, poor treatment options and low-quality evidence plagued care for patients with rifampin-resistant tuberculosis. The advent of new drugs to treat tuberculosis and enhanced funding now permit randomized, controlled trials of shortened-duration, all-oral treatments for rifampin-resistant tuberculosis. We conducted a phase 3, multinational, open-label, randomized, controlled noninferiority trial to compare standard therapy for treatment of fluoroquinolone-susceptible, rifampin-resistant tuberculosis with five 9-month oral regimens that included various combinations of bedaquiline (B), delamanid (D), linezolid (L), levofloxacin (Lfx) or moxifloxacin (M), clofazimine (C), and pyrazinamide (Z). Participants were randomly assigned (with the use of Bayesian response-adaptive randomization) to receive one of five combinations or standard therapy. The primary end point was a favorable outcome at week 73, defined by two negative sputum culture results or favorable bacteriologic, clinical, and radiologic evolution. The noninferiority margin was -12 percentage points. Among the 754 participants who underwent randomization, 699 were included in the modified intention-to-treat analysis, and 562 in the per-protocol analysis. In the modified intention-to-treat analysis, 80.7% of the patients in the standard-therapy group had favorable outcomes. The risk difference between standard therapy and each of the four new regimens that were found to be noninferior in the modified intention-to-treat population was as follows: BCLLfxZ, 9.8 percentage points (95% confidence interval [CI], 0.9 to 18.7); BLMZ, 8.3 percentage points (95% CI, -0.8 to 17.4); BDLLfxZ, 4.6 percentage points (95% CI, -4.9 to 14.1); and DCMZ, 2.5 percentage points (95% CI, -7.5 to 12.5). Differences were similar in the per-protocol population, with the exception of DCMZ, which was not noninferior in that population. The proportion of participants with grade 3 or higher adverse events was similar across the regimens. Grade 3 or higher hepatotoxic events occurred in 11.7% of participants overall and in 7.1% of those receiving standard therapy. Consistent results across all the analyses support the noninferior efficacy of three all-oral shortened regimens for the treatment of rifampin-resistant tuberculosis. (Funded by Unitaid and others; endTB ClinicalTrials.gov number, NCT02754765.).

30 June 2015 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
GVGustavo E. Velásquez
Gustavo E. Velásquez
OAOmowunmi Aibana
Omowunmi Aibana
ELEmilia J. Ling
Emilia J. Ling
IDIbrahim Diakite
Ibrahim Diakite
EMEric Q. Mooring
Eric Q. Mooring
MMMegan B. Murray
Megan B. Murray
We systematically reviewed the literature to estimate the incubation and latent periods of Ebola virus disease. We found limited epidemiological data from individuals with discrete 1-day exposures. Available data suggest that the incubation and latent periods may differ, and mathematical models may be improved by distinguishing between the two periods.

11 April 2014 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
GVGustavo E. Velásquez
Gustavo E. Velásquez
MBMercedes C. Becerra
Mercedes C. Becerra
IGIrina Y. Gelmanova
Irina Y. Gelmanova
APAlexander D. Pasechnikov
Alexander D. Pasechnikov
AYAskar Yedilbayev
Askar Yedilbayev
SKSalmaan Keshavjee
Salmaan Keshavjee
Background. Evidence is sparse regarding the optimal construction of regimens to treat multidrug-resistant (MDR) tuberculosis disease due to strains of Mycobacterium tuberculosis resistant to at least both isoniazid and rifampin. Given the low potency of many second-line antituberculous drugs, we hypothesized that an aggressive regimen of at least 5 likely effective drugs during the intensive phase, including a fluoroquinolone and a parenteral agent, would be associated with a reduced risk of death or treatment failure. Methods. We conducted a retrospective cohort study of patients initiating MDR tuberculosis treatment between 2000 and 2004 in Tomsk, Russian Federation. We used a multivariate Cox proportional hazards model to assess whether monthly exposure to an aggressive regimen was associated with the risk of death or treatment failure. Results. Six hundred fourteen individuals with confirmed MDR tuberculosis were eligible for analysis. On multivariable analysis that adjusted for extensively drug-resistant (XDR) tuberculosis—MDR tuberculosis isolates resistant to fluoroquinolones and parenteral agents—we found that monthly exposure to an aggressive regimen was significantly associated with a lower risk of death or treatment failure (hazard ratio, 0.52 [95% confidence interval, .29–.94]; P = .030). Conclusions. Receipt of an aggressive treatment regimen was a robust predictor of decreased risk of death or failure during MDR tuberculosis treatment. These findings further support the use of this regimen definition as the benchmark for the standard of care of MDR tuberculosis patients and should be used as the basis for evaluating novel therapies.

1 August 2017 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
PDF file
CPCharles A Peloquin
Charles A Peloquin
GVG. E. Velásquez
G. E. Velásquez
LLLeonid Lecca
Leonid Lecca
RCRoger Calderon
Roger Calderon
JCJ. Coit
J. Coit
GDG. Davies
G. Davies
Rifamycins exhibit concentration-dependent killing of Mycobacterium tuberculosis; higher exposures potentially induce better outcomes. We randomized 180 tuberculosis patients in Peru to 10, 15, and 20 mg/kg/day of rifampin. 168 had noncompartmental pharmacokinetic analyses: 67% were sampled twice; 33% six times. Doses were well-tolerated. Median (interquartile range) AUC0-6 was 24.9 (17.6-32.1), 43.1 (30.3-57.5), and 55.5 (35.7-73.2) h*mcg/mL; median Cmax in the experimental arms reached the target of 8 mcg/mL. Continued investigation of higher rifampin doses is warranted.

11 November 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
OAOmowunmi Aibana
Omowunmi Aibana
XAXeno Acharya
Xeno Acharya
CHChuan-Chin Huang
Chuan-Chin Huang
MBMercedes C. Becerra
Mercedes C. Becerra
JGJerome T. Galea
Jerome T. Galea
MMMegan Murray
Megan Murray
Studies show obesity decreases risk of tuberculosis (TB) disease. There is limited evidence on whether high body mass index also protects against TB infection; how very high body mass indices influence TB risk; or whether nutritional status predicts this risk in children. We assessed the impact of body mass index on incident TB infection and disease among adults and children. We conducted a prospective cohort study among household contacts of pulmonary TB cases in Lima, Peru. We determined body mass index at baseline and followed participants for one year for TB infection and disease. We used Cox proportional regression analyses to estimate hazard ratios for incident TB infection and disease. We enrolled 14,044 household contacts, and among 6853 negative for TB infection and disease at baseline, 1787 (26.1%) became infected. A total of 406 contacts developed secondary TB disease during follow-up. Body mass index did not predict risk of TB infection but overweight household contacts had significantly decreased risk of TB disease (HR 0.48; 95% CI 0.37–0.64; p <0.001) compared to those with normal weight. Among adults, body mass index ≥ 35 kg/m2 continued to predict a lower risk of TB disease (HR 0.30; 95% CI 0.12–0.74; p 0.009). We found no association between high body mass index and TB infection or disease among children under 12 years of age. High body mass index protects adults against TB disease even at levels ≥ 35 kg/m2. This protective effect does not extend to TB infection and is not seen in children.